Abstract 4581
Background
The definitive treatment for localized SCCA is ChRT in combination with infusional 5-FU. A meta-analysis of published studies conducted by our group showed that HIV-positive patients (pts) are less cured by ChRT. However, short follow up times may have underestimated the true response rate of HIV-positive pts. We aimed to compare the timing to achieve CR between HIV-negative and positive pts and outcomes according to chemotherapy regimen (Nigro vs ACT2).
Methods
Retrospective multicenter comparative cohort of consecutive pts with histological diagnosis of SCCA and localized disease who received definitive ChRT. Pts’ characteristics and outcomes were compared according to HIV status. The primary endpoint was CR rate defined by absence of clinical and radiological evidence of disease.
Results
A total of 179 patients with SCCA were included: 43 (24%) were HIV-positive and 136 (76%) were HIV-negative. HIV-positive pts were more commonly men: 28 (65%) vs 24 (17.6%) (p < 0.001) and had clinical stage III: 22 (51%) vs 60 (44%). The overall CR rate was 74.4% vs 83.1% for HIV-positive and negative pts, respectively (P = 0.206). Among pts who achieved a CR (N = 145), the rates of CR for HIV-positive vs negative pts were, respectively: 32.5% vs 67% at 6 months evaluation and 41.8% vs 16.1% after 6 months (6 to 18 months) post ChRT (p < 0.001). More HIV-positive pts underwent salvage surgery: 14 (35.2%) vs 21 (15.4%) (p < 0.01). The overall CR rates of HIV-positive pts were 71.4% (10 out of 14) with ACT2 and 63% (14 out of 22) with Nigro. For HIV-negative, the CR rates were: 90.3% (28 out of 31) for ACT2 and 80.2 % (73 out of 91) for Nigro.
Conclusions
Delayed CR was more frequently observed among HIV-positive pts. This finding has clinical implications because waiting longer to define CR among these pts may prevent unnecessary anorectal amputations.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4331 - STING Agonist, ADU-S100, Yields Potent Antitumor Activity and Therapeutically Favorable Immune Profile in an Esophageal Adenocarcinoma Model
Presenter: Ali Zaidi
Session: Poster Display session 2
Resources:
Abstract
1770 - Increased assessment of HER2 in metastatic gastroesophageal cancer patients: a nationwide population-based cohort study
Presenter: Willemieke Dijksterhuis
Session: Poster Display session 2
Resources:
Abstract
3755 - A new docetaxel (DOC)-based triplet regimen does not improve the outcome of metastatic (M) or locally advanced (LA) gastric cancer (GC) as compared with an epirubicin (EPI) standard triplet regimen: a GISCAD trial.
Presenter: Roberto Labianca
Session: Poster Display session 2
Resources:
Abstract
2439 - The analysis of T cell subsets and clinical efficacy of immune checkpoint blockades in patients with advanced gastric cancer using multiplex immunohistochemistry
Presenter: Tae-yong Kim
Session: Poster Display session 2
Resources:
Abstract
2211 - First-line pembrolizumab (P), trastuzumab (T), capecitabine (C) and oxaliplatin (O) in HER2-positive metastatic esophagogastric adenocarcinoma.
Presenter: Yelena Janjigian
Session: Poster Display session 2
Resources:
Abstract
3046 - Monitoring patient-specific mutation in ctDNA and CTC for tumor response evaluation after neoadjuvant chemotherapy in locally advanced gastric cancer (NCT03425058)
Presenter: Tao Fu
Session: Poster Display session 2
Resources:
Abstract
4628 - Gastric cancer screening in BRCA 2 gene mutation carriers: should it be recommended?
Presenter: Inês Oliveira
Session: Poster Display session 2
Resources:
Abstract
2127 - Interim analysis of an observational/translational study for nivolumab treatment in advanced gastric cancer: JACCRO GC-08 (DELIVER trial)
Presenter: Yu Sunakawa
Session: Poster Display session 2
Resources:
Abstract
2264 - Prediction of S-1 adjuvant chemotherapy efficacy in Stage II/III gastric cancer treatment based on comprehensive gene expression analysis
Presenter: Masanori Terashima
Session: Poster Display session 2
Resources:
Abstract
2444 - Assessing the clinical utility of circulating tumour DNA through longitudinal liquid biopsy sampling in Oesophageal adenocarcinoma
Presenter: Emma Ococks
Session: Poster Display session 2
Resources:
Abstract